Health Care Services

Credit Suisse reiterates its Hold rating on Lincare Holdings (NASDAQ: LNCR) and raises its price target by $1.50 to $29 as the company's Q4 results came in largely in line with expectations. Credit Suisse comments, "LNCR reported Q4 revs of $492.2M (+16.6% yoy), driven by +6% internal/organic, +...

Deutsche Bank has downgraded Lincare Holdings (NASDAQ: LNCR) from Buy to Hold and maintains its $27.50 price target.

LHC Group Inc. (Nasdaq: LHCG) The Company also announced its net revenue and fully diluted earnings per share guidance for fiscal year 2012. Fiscal year net service revenue is expected to be in the range of $640 million to $660 million, and fully diluted earnings per share are expected to be in...

Piper Jaffray initiated coverage of LHC Group (NASDAQ: LHCG) with an Overweight rating and $15 price target in a research report published today. In the report, Piper Jaffray said, "LHCG is one of the leading home health providers with a slightly differentiated strategy as the majority of its home...

Deutsche Bank has published a research report on LabCorp of America (NYSE: LH) commenting on the company's deal completion with Orchid Cellmark expected in April 2012. In the report, Deutsche Bank writes, "After an extended review, the US Federal Trade Commission has approved the acquisition, with...

Shares of Laboratory Corporation of America (NYSE: LH) are lower on the session by 0.58%, currently trading at $85.84. The stock has been moving largely higher over the past two months and is currently trading above the 50-day moving average. Options traders are focusing on puts today. The strike...

In a company note, Piper Jaffray maintains its Overweight rating and $102 price target on LabCorp of America (NYSE: LH) on lab tour highlights of the company's leadership, innovation and clinical trials business. Piper Jaffray says, “Palmetto's LCD for molecular diagnostics not likely to have a...

Laboratory Corporation of America Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on December 9, 2011, LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May 17...

Citi Investment Research is out with a research report on Laboratory Corp of America (NYSE: LH) and it has a Buy rating and is raising its price target to $83 from $82. In a note to clients, Citi Investment Research writes, "3Q11 revenue, gross margin, operating income and cash EPS (with...

AutoNation Inc (NYSE: AN) reported a 24% rise in its third-quarter net profit on Thursday. AutoNation's quarterly net profit surged to $70.7 million, or $0.48 per share, from $56.9 million, or $0.38 per share, in the year-ago period. Its revenue gained 7% to $3.5 billion. However, analysts were...

Laboratory Corp of America Holdings (NYSE: LH) reported a 4.1% drop in its third-quarter profit and lifted its adjusted earnings forecast for the year. Laboratory Corp now projects adjusted earnings of $6.28 to $6.33 per share, versus its earlier forecast of $6.17 to $6.32 per share. Laboratory...

According to Deutsche Bank, LabCorp of America (NYSE: LH) Buy rating is maintained. Deutsche Bank said that it believes buy-side expectations for LH are relatively low, but it's heard concern from many investors that LH might use Q3's CC to signal lower near/medium-term growth in light of the...

Citi is out with its report today on Lincare Holdings (NASDAQ: LNCR), maintaining Neutral. In its report, Citi writes, "We rate LNCR Neutral due to a recurring history of government reimbursement reductions. We continue to believe that LNCR could be a long-term winner from the consolidation of the...

According to Jefferies, Lincare Holdings (NASDAQ: LNCR) price target is lowered to $25. Jefferies said that despite LNCR's strong management team and good cash flow outlook, it remains reluctant to get aggressive with LNCR at this point given soft organic growth trends, declining margins, comp...

A report from Oppenheimer reiterates its Perform rating and lowers its price target from $27 to $32 on Lincare Holdings (NASDAQ: LNCR). The report states, “ Lincare reported 3Q11 EPS of $0.48, topping our estimate of $0.47 and in line with the Street. The company's $150M share repurchase this...